OVERVIEW

To deliver drugs to patients with unmet medical needs as soon as possible, regulatory agencies must strengthen their review systems and shorten their review periods. Introducing expedited review systems, for example, will accelerate the development and delivery of new drugs from the regulatory side. R&D into new drugs by both companies and academia incorporate the latest science but still face challenges in addressing these unmet medical needs. Surrounding all this effort from industry, government and academia, the global development environment is also rapidly evolving day by day; grasping the impact of this evolution has become an important foundation for successfully meeting this challenge.

DIA’s 12th Asia New Drug Conference will share information on current and anticipated steps to collaboratively move forward. These include already established accelerated review pathways as well as progress and implementation of the ICH E17 guideline for planning and designing multiregional clinical trials, which will be specifically addressed by an expert panel followed by mutual discussion between our audience and speakers. Experts from pharmaceutical companies and regulatory agencies will also provide the latest information about industry and regulatory challenges and initiatives, including next steps and how to proceed with tasks, in each Asian country. Topics related to risk and labeling management in various medical and regulatory environments have been prominently discussed in each country, and this conference provides a forum to further discuss these topics. We will also examine the remarkable change and recent regulatory reform introduced by the China FDA.

DIA’s 12th DIA Asia New Drug Conference presents an opportunity for you to discover and consider new approaches for drug development in Asia. Now is the time for us to rise to meet this challenge. Now is the time for you to participate.

WHO SHOULD ATTEND

The program will benefit those with the following interests:
• Clinical development
• Medical affairs and market
• Regulatory affairs
• Academic organizations
• Clinical study sites
• Regulatory agencies
• CROs and SMOs

Tabletop Exhibit Opportunities Available
For more information, contact DIA Japan
Tel: +81.3.6214.0574 | Fax: +81.3.3278.1313
Email: Japan@DIAglobal.org

Simultaneous Translation Available
### 9:00-9:30  REGISTRATION

### 9:30-9:40  WELCOME AND OPENING REMARKS

**Ko SEKIGUCHI**  
Director, DIA Japan

### 9:40-10:10  KEYNOTE ADDRESS

**Ari FUJISHIRO**  
Senior Director, Regulatory Affairs Group, Asia Development Department, R&D Division, Daiichi Sankyo Co., Ltd.

**Evolution of Asian Regulatory Perspectives on Drug Development - Towards Convergence/Harmonization, Collaboration and Networking**  
Yoshikazu HAYASHI, PhD  
Associate Center Director (for New Drug Review), PMDA

### 10:10-11:55  SESSION 1

**Expedited Review Pathways in Asia**

**SESSION CHAIR**  
Masayoshi SHIBATSUJI  
Coordination Officer for Review of Breakthrough Products (SAKIGAKE) / Coordination Officer for the Practical Application of Innovation, Advancements, PMDA

Earlier access to new drugs has recently been realized as a result of improved regulations to approve new drugs earlier at the global level. In this session, Asian regulatory experts will explain expedited review pathways in each region, followed by a panel discussion to deeply discuss various strategies that deliver innovative new drugs earlier to patients in Asia.

**Expedited Pathways for Biopharmaceuticals in Korea**  
**Kyungtak NAM**  
Senior Scientific Officer, Biopharmaceuticals Review Management Division, Biopharmaceuticals & Herbal Medicine Evaluation Department, NIFDS, MFDS, Republic of Korea

**Expedited Review Process and Timeline (TFDA)**  
**Lien-Cheng CHANG, PhD**  
Section Chief, Division of Medicinal Products, TFDA, MoHW, Chinese Taipei

**Expedited Program in China**  
**Wendy YAN, MBA**  
Senior Vice President, Global Head of Regulatory Affairs, BeiGene, China

**Panel Discussion**

**PANELISTS**  
All speakers in Keynote Address and Sessions 1

### 11:55-13:10  LUNCH BREAK

### 13:10-15:00  SESSION 2 (PART 1)

**Regulatory and Industry Challenges to ICH E17 Implementation**

**SESSION CHAIR**  
Yoshiaki UYAMA, PhD  
Director, Office of Medical Informatics and Epidemiology, PMDA

At the November 2017 ICH Geneva meeting, the ICH E17 guideline “General Principles for Planning and Design of Multi-Regional Clinical Trials (MRCTs)” was finalized. Promoting multiregional drug development increases the number of regions participating in a MRCT; regional regulatory authorities and industry are being expected to challenge in consistency evaluation between overall and regional results, and sample size allocations to regions. In this session, several regulatory authorities will provide their perspective on current difficulties with not only planning and designing MRCTs but also data interpretation and challenges from implementing this guideline. Panel discussion will exchange various opinions from regulatory authorities and additional industry panelists.

**Overview of ICH E17**  
Yoshiaki UYAMA, PhD  
Director, Office of Medical Informatics and Epidemiology, PMDA

**T-CDE’s Experiences to Review MRCT Results and Expectations for E17 Guideline**  
I-Chun LAI, MD, MS  
Director, Center of Consultation, T-CDE, Chinese Taipei

**MFDS’s Experiences to Review MRCT Data**  
Mee Ryung AHN, PhD  
Senior Scientific Officer, Gastroenterology and Metabolism Products Division, Drug Evaluation Department, NIFDS, MFDS, Republic of Korea

**PMDA’s Experiences to Review MRCT Results and Expectations for E17 Guideline**  
Yoko AOI, PhD  
Planning and Coordination Officer, Office of International Cooperation, PMDA

### 15:00-15:30  COFFEE BREAK

### 15:30-16:30  SESSION 2 (PART 2)

**Panel Discussion**

**PANELISTS**  
All speakers in Sessions 2 and 3

**Shun JIN, MBA**  
Head, Regulatory Affairs, Asia Pacific, Abbott Laboratories (Singapore) Pte Ltd

In ASEAN, the regulatory environment is changing very fast. The dynamic regulatory requirement brings challenges to the industry. In 2017, the pharmaceutical law in Vietnam has been updated and implemented. Industry is trying to digest the new requirements in this regulation and the speaker from DAV will give the explanation on the key updates in the new regulation. In addition, there will be another presentation from industry perspective. The session explores the ASEAN pharmaceutical environment from the onset of the ASEAN Consultative Committee for Standards and Quality (ACCSQ) Pharmaceutical Product Working Group (PPWG), Technical Working Groups (TWG), Implementation Working Group (IWG) and ASEAN guidelines. Providing insights on the latest development in PPWG, updates and future area of guidance discussion. Discussing the challenges faced by industry members and opportunities for industry in creating favourable regulatory environment in expediting approval of innovative medicines for patients in ASEAN.

**Regulatory Environment in Vietnam (tentative)**  
Mai Huong NGUYEN  
Officer, Drug Registration Division, Drug Administration of Vietnam (DAV), Vietnam

**ASEAN Pharmaceutical Environment: Industry Perspective on Challenges, Opportunities and Prospects of Partnerships**  
Kum Cheun (KC) WONG  
Head of Asia Pacific, Regulatory & Development Policy, Novartis Asia Pacific Pharmaceuticals Pte. Ltd., Singapore

### 17:45-19:30  NETWORKING RECEPTION

**Private Social Function Policy**  
DIA does not allow hospitality functions to be held during any DIA meeting sessions, scheduled exhibit hours, or social events. Therefore, the hours noted below are the only hours that are acceptable for hospitality functions.

- **Sunday, March 25**  
  All times are acceptable
- **Monday, March 26**  
  Before 8:00 and after 21:00
- **Tuesday, March 27**  
  Before 8:00 and after 19:00
DAY 2 | Tuesday, March 27, 2018

9:00-9:30  REGISTRATION

9:30-10:50  SESSION 3 (PART 1)
Chance of Collaboration among Asian Health Authorities – GCP & AMR

SESSION CHAIR
Hiroshi WATANABE, MD, PhD
Head of Center for Clinical Sciences (CCS), National Center for Global Health and Medicine (NCGM)
Professor, Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine

GCP Inspection in Japan
Hiroshi DOGUCHI, DVM, PhD
GCP Inspector, Office of Non-clinical and Clinical Compliance, PMDA

TFDA GCP Inspection
Lien-Cheng CHANG, PhD
Section Chief, Division of Medicinal Products, TFDA, MoHW, Chinese Taipei

GCP Inspection in China (tentative)
Cathy LIU
Senior GCP Strategy Lead, Product Development Quality Assurance (PDQA), Roche PD Shanghai, China

GCP Inspection under MFDS (tentative)
Jung Eun JO
Clinical Trials Management Division, Pharmaceutical Safety Bureau, MFDS, Republic of Korea

10:50-11:10  COFFEE BREAK

11:10-11:50  SESSION 3 (PART 2)
Chance of Collaboration among Asian Health Authorities – GCP & AMR

SESSION CHAIR
Hiroshi Watanabe, MD, PhD
Head of Center for Clinical Sciences (CCS), National Center for Global Health and Medicine (NCGM)
Professor, Department of Clinical Pharmacology & Therapeutics, Hamamatsu University School of Medicine

AMR (tentative)
Junko SATO, PhD
Office Director, Office of International Cooperation, PMDA

The AMR Projects
Antonio Fredelindo Dela Resma VILLANUEVA, MD
Project Manager, Department of International Trial, Center for Clinical Sciences (CCS), National Center for Global Health and Medicine (NCGM)

11:50-13:05  LUNCH

13:05-15:30  SESSION 4
Drug Development in China: Regulatory Reform and the Impact

SESSION CHAIR
Ling SU, PhD
Professor and Director, Institute of Drug Regulatory Science, Shenyang Pharmaceutical University / Venture Partner, Lilly Asia Ventures

The regulatory reform in China that started in mid-2015 has entered the third year and is progressing well. In 2017, the China Food and Drug Administration (CFDA) became a regulatory member of ICH. These changes have brought about major changes in the pharmaceutical R&D and regulatory processes in China. The clinical trial review and approval process, the increasing trend of in- and out-license collaborations and simultaneous development, and the Marketing Authorization Holder program are among the most notable areas enhanced by the reform. In these session, speakers from the CFDA and the industry will share with the audience the update of the reform progress and their experience and perspectives on how the reform has changed the drug development in China.

Update on Regulatory Reform
Dan ZHANG, MD, MPH
Executive Chairman, Fountain Medical Development Ltd., China

Experience of MAH Pilot in China
Ni CHEN, MD, PhD
CEO, Shanghai Junshi TopAlliance Biosciences, China

Experience of In-Licensing Product and Leveraging on Overseas Early Clinical Data for China Development
Min DONG, PhD
SVP, Clinical Development, EOC Pharma, China

Accelerating the Development of Life-Changing Medicines for Chinese Patients through Innovation and Partnership
George CHEN, MD, MBA
Senior VP, Global Medicines Development, Head of China Development Unit, AstraZeneca China

Panel Discussion
PANELISTS
All speakers in this Session

15:30-16:00  COFFEE BREAK

16:00-17:30  SESSION 5
What’s New for Labeling and Risk Management in East Asia?

SESSION CHAIR
Rie MATSUI, RPh
Director, Regional Labeling Head for Asia, International Labeling Group, Pfizer Japan Inc.

Labeling is the major “routine” risk minimization element in the risk management plan (RMP). This session provides updates on labeling and risk management in East Asia, in response to regulations that have been revised and/or newly issued in this region. The status of implementing RMPs, including patient information, in Korea, as well as labeling and labeling updates in China will be discussed. This session will also address one of the hottest topics across all regions, the status of electronic labeling. Panel discussion will address how ICH E17 will impact RMPs and labeling in this region.

Regulation for RMP under MFDS and Recent Experiences
Bee KIM
Country Patient Safety Head, Korea, Novartis Patient Safety, GDD (Global Drug Development), Novartis Korea Ltd., Republic of Korea

Labeling Regulation in China
Jason Chen, MPHarm
International Labeling Asia Team Lead, Pfizer (China) R&D Co., Ltd., China

Emerging Trends of Electronic Labelling in Asia Pacific
Vicky HAN
Senior Director, Asia Pacific Regulatory Policy Lead, Global Regulatory Affairs, Janssen Asia Pacific, Johnson & Johnson Pte. Ltd., Singapore

Panel Discussion
PANELISTS
All speakers in this Session

17:30-17:35  CLOSING REMARKS

Unless otherwise disclosed, DIA acknowledges that the statements made by speakers are their own opinion and not necessarily that of the organization they represent, or that the DIA.

Speakers and agenda are subject to change without notice.

Recording of any DIA tutorial/workshop/meeting information in any type of media, is prohibited without prior written consent from DIA.
REGISTRATION FORM: Register online or forward to DIA Japan, Nihonbashihoncho, Chuo-ku, Tokyo 103-0023 Japan
tel +81.3.6214.0574 • fax +81.3.3278.1313

12th DIA Asia New Drug Conference in Japan
Event #18302 • March 26-27, 2018 | TOC Ariake Convention Hall, Tokyo
Address: 3-5-7 Ariake, Koto-ku, Tokyo 135-0063
DIA will send participants a confirmation letter within 10 business days after receipt of their registration.

Registration Fees: If DIA cannot verify your membership, you will be charged the nonmember fee. Registration fee includes refreshment breaks and reception (if applicable), and will be accepted by mail, fax, or online.

Join DIA now to save on future meetings and to enjoy the benefits of membership for a full year: DIAGlobal.org/Membership

☐ I DO want to be a DIA member
☐ I DO NOT want to be a DIA member

<table>
<thead>
<tr>
<th>Fees incl. 8% Consumption Tax</th>
<th>Industry</th>
</tr>
</thead>
<tbody>
<tr>
<td>Early Bird (until March 12, 2018)</td>
<td>¥63,720</td>
</tr>
<tr>
<td>After March 13, 2018</td>
<td>¥69,120</td>
</tr>
<tr>
<td>Government, Non Profit</td>
<td></td>
</tr>
<tr>
<td>Early Bird (until March 12, 2018)</td>
<td>¥24,300</td>
</tr>
<tr>
<td>After March 13, 2018</td>
<td>¥27,000</td>
</tr>
<tr>
<td>Government, Medicals:</td>
<td></td>
</tr>
<tr>
<td>Early Bird (until March 12, 2018)</td>
<td>¥24,300</td>
</tr>
<tr>
<td>After March 13, 2018</td>
<td>¥27,000</td>
</tr>
<tr>
<td>Membership</td>
<td></td>
</tr>
<tr>
<td>Non-Member</td>
<td></td>
</tr>
<tr>
<td>Government, Non Profit</td>
<td>¥88,020</td>
</tr>
<tr>
<td>Medicals</td>
<td>¥59,960</td>
</tr>
<tr>
<td>Non-Member</td>
<td></td>
</tr>
<tr>
<td>Government, Non Profit</td>
<td>¥45,900</td>
</tr>
<tr>
<td>Medicals</td>
<td>¥34,020</td>
</tr>
<tr>
<td>Membership</td>
<td></td>
</tr>
<tr>
<td>2-Year Membership</td>
<td>¥18,900</td>
</tr>
<tr>
<td>Academia Membership (Academia, Medicals)*</td>
<td>¥12,960</td>
</tr>
</tbody>
</table>

Early Bird Deadline: March 12, 2018
* To register for Academia Membership, please send this form to DIA Japan office by fax or e-mail.

Please check the applicable category:
☐ Academia  ☐ Government  ☐ Industry  ☐ Medicals
☐ CSO (Contract research/service organization)
☐ Student (Call for registration information)

Last Name
First Name
M.I.
Job Title
Dr.  ☐  Ms.  ☐  Mr.  ☐
Department
Company
Address (As required for postal delivery to your location)
City  State  Zip/Postal  Country

Email Required for confirmation
Phone Number Required  Fax Number

TRAVEL AND HOTEL
Hotel Sunroute Ariake is convenient accommodation adjacent to the venue. To reserve, please contact Hotel Sunroute Ariake below.
Address: 3-6-6 Ariake, Koto-ku, Tokyo 135-0063
Telephone: +81-(0)3-5530-3610 / Fax: +81-(0)3-5530-3611
Email: ariake_otoiawase@sunroute.jp
URL: http://www.hotelsunrouteariake.jp

CANCELLATION POLICY: On or before March 19, 2018
Administrative fee that will be withheld from refund amount:
Member or Nonmember = ¥20,000
Government/Academia/Nonprofit (Member or Nonmember) = ¥10,000
Cancellations must be in writing and be received by the cancellation date above. Registrants who do not cancel by that date and do not attend will be responsible for the full registration fee paid. Registrants are responsible for cancelling their own hotel and airline reservations. You may transfer your registration to a colleague at any time but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. Substitute registrants will be responsible for nonmember fee, if applicable.
DIA does NOT allow registrants to pass name badges to others. DIA may ask attendees to show identifications, if necessary.
DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.

PURPOSE OF USE OF PERSONAL INFORMATION
The personal information provided by this application will be used to contact you with information about upcoming events, programs, products and services of DIA. In addition, your name and organization name will be listed in the Attendee List which will be distributed on site to the participants of this event. Submission of this application will be regarded as you agreed to it, but if not, please contact DIA Japan.

PHOTOGRAPHY POLICY
By attending any DIA events, you give permission for images of you (captured during the conference through video, photo, and/or digital camera) to be used in DIA promotional materials, publications, and/or website and waive any and all rights including, but not limited to compensation or ownership.

PAYMENT OPTIONS
Register online at www.DIAglobal.org or check payment method.

☐ BANK TRANSFER:
You will receive an invoice with bank information detail by Email after registration completion.
All local and overseas charges incurred for the bank transfer must be borne by payer.

☐ CREDIT CARD (VISA, MasterCard or JCB only):
☐ VISA  ☐ MasterCard  ☐ JCB

Card No.
Exp. (mm/yy)
Cardholder Name
Signature

CONTACT INFORMATION
Contact the DIA Japan office in Tokyo for further information.
Tel: +81.3.6214.0574 | fax: +81.3.3278.1313
Email: Japan@DIAglobal.org
www.DIAJapan.org